Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome
Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome
About this item
Full title
Author / Creator
Publisher
Dordrecht: Springer Netherlands
Journal title
Language
English
Formats
Publication information
Publisher
Dordrecht: Springer Netherlands
Subjects
More information
Scope and Contents
Contents
Comprehensive annual screening reduces cancer-related mortality in Li-Fraumeni syndrome (LFS), a cancer-prone disorder caused by pathogenic germline
TP53
variants. Blood tests at months 4 and 8 between annual screening are recommended but their effectiveness in early cancer detection has not been established. Interim blood counts and inflamma...
Alternative Titles
Full title
Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2536484510
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2536484510
Other Identifiers
ISSN
1389-9600,1573-7292
E-ISSN
1573-7292
DOI
10.1007/s10689-021-00265-x
